MIR34A, microRNA 34a, 407040

N. diseases: 428; N. variants: 5
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C2711227
Disease: Steatohepatitis
Steatohepatitis
0.400 AlteredExpression disease BEFREE After normalization of the steatosis-related circRNA by expression vector, analysis of miR-34a activity, peroxisome proliferator-activated receptor (PPAR)α level, and expression of downstream genes were carried out so as to reveal its impact on the miR-34a/PPARα regulatory system. 29391755 2018
CUI: C2711227
Disease: Steatohepatitis
Steatohepatitis
0.400 Biomarker disease BEFREE Amelioration of hepatic steatosis is associated with modulation of gut microbiota and suppression of hepatic miR-34a in <i>Gynostemma pentaphylla</i> (Thunb.) Makino treated mice. 30555521 2018
CUI: C2711227
Disease: Steatohepatitis
Steatohepatitis
0.400 Biomarker disease BEFREE Activating AMPK<i>α</i> negatively regulates Egr1 to inhibit inflammatory cytokines in high glucose. miR-34a inhibition increases phosphorylated AMPK<i>α</i> through mediating SIRT1 to suppress the development of fatty liver. 29681936 2018
CUI: C2711227
Disease: Steatohepatitis
Steatohepatitis
0.400 Biomarker disease BEFREE These findings indicate a circRNA_0046367/miR-34a/PPAR<i>α</i> regulatory system underlying hepatic steatosis. 29018509 2017
CUI: C2711227
Disease: Steatohepatitis
Steatohepatitis
0.400 AlteredExpression disease BEFREE We found that hepatic miR-34a expression was upregulated in ethanol-fed mice and heavy drinkers with steatohepatitis compared with respective controls. 29128099 2017
CUI: C2711227
Disease: Steatohepatitis
Steatohepatitis
0.400 AlteredExpression disease BEFREE Effect of miR-34a in regulating steatosis by targeting PPARα expression in nonalcoholic fatty liver disease. 26330104 2015
CUI: C2711227
Disease: Steatohepatitis
Steatohepatitis
0.400 Biomarker disease BEFREE Here we show that hepatocyte nuclear factor 4α (HNF4α), a liver-enriched nuclear hormone receptor, is markedly inhibited, whereas miR-34a is highly induced in patients with non-alcoholic steatohepatitis, diabetic mice and mice fed a high-fat diet. miR-34a is essential for HNF4α expression and regulates triglyceride accumulation in human and murine hepatocytes. miR-34a inhibits very low-density lipoprotein secretion and promotes liver steatosis and hypolipidemia in an HNF4α-dependent manner. 26100857 2015
CUI: C2711227
Disease: Steatohepatitis
Steatohepatitis
0.400 Biomarker disease BEFREE p53 and its transcriptional target miRNA34a have been implicated in the pathogenesis of fatty liver. 23211317 2013
CUI: C2711227
Disease: Steatohepatitis
Steatohepatitis
0.400 Biomarker disease CTD_human The miR-34a/NAMPT axis presents a potential target for treating obesity- and aging-related diseases involving SIRT1 dysfunction like steatosis and type 2 diabetes. 23834033 2013
CUI: C2711227
Disease: Steatohepatitis
Steatohepatitis
0.400 Biomarker disease BEFREE MicroRNA-34a (miR-34a) is the most highly elevated hepatic miR in obese mice and is also substantially elevated in patients who have steatosis, but its role in obesity and metabolic dysfunction remains unclear. 22988100 2012
CUI: C2711227
Disease: Steatohepatitis
Steatohepatitis
0.400 AlteredExpression disease BEFREE Again, miR-122 and miR-34a levels positively correlated with disease severity from simple steatosis to steatohepatitis. 21886843 2011
CUI: C0015695
Disease: Fatty Liver
Fatty Liver
0.360 Biomarker disease BEFREE Amelioration of hepatic steatosis is associated with modulation of gut microbiota and suppression of hepatic miR-34a in <i>Gynostemma pentaphylla</i> (Thunb.) Makino treated mice. 30555521 2018
CUI: C0015695
Disease: Fatty Liver
Fatty Liver
0.360 Biomarker disease BEFREE Dysregulation of circRNA_0046366/miR-34a/PPARα signaling may be a novel epigenetic mechanism underlying hepatocellular steatosis. circRNA_0046366 serves as a potential target for the treatment of hepatic steatosis. 29391755 2018
CUI: C0015695
Disease: Fatty Liver
Fatty Liver
0.360 Biomarker disease BEFREE Activating AMPK<i>α</i> negatively regulates Egr1 to inhibit inflammatory cytokines in high glucose. miR-34a inhibition increases phosphorylated AMPK<i>α</i> through mediating SIRT1 to suppress the development of fatty liver. 29681936 2018
CUI: C0015695
Disease: Fatty Liver
Fatty Liver
0.360 Biomarker disease BEFREE These findings indicate a circRNA_0046367/miR-34a/PPAR<i>α</i> regulatory system underlying hepatic steatosis. 29018509 2017
CUI: C0015695
Disease: Fatty Liver
Fatty Liver
0.360 Biomarker disease BEFREE Here we show that hepatocyte nuclear factor 4α (HNF4α), a liver-enriched nuclear hormone receptor, is markedly inhibited, whereas miR-34a is highly induced in patients with non-alcoholic steatohepatitis, diabetic mice and mice fed a high-fat diet. miR-34a is essential for HNF4α expression and regulates triglyceride accumulation in human and murine hepatocytes. miR-34a inhibits very low-density lipoprotein secretion and promotes liver steatosis and hypolipidemia in an HNF4α-dependent manner. 26100857 2015
CUI: C0015695
Disease: Fatty Liver
Fatty Liver
0.360 Biomarker disease CTD_human Elevated microRNA-34a in obesity reduces NAD+ levels and SIRT1 activity by directly targeting NAMPT. 23834033 2013
CUI: C0015695
Disease: Fatty Liver
Fatty Liver
0.360 Biomarker disease BEFREE p53 and its transcriptional target miRNA34a have been implicated in the pathogenesis of fatty liver. 23211317 2013
CUI: C0028754
Disease: Obesity
Obesity
0.350 Biomarker disease BEFREE In addition, these genes are targeted by miRNAs related to schizophrenia (mir-34a) and obesity (mir-19b). 31447353 2019
CUI: C0028754
Disease: Obesity
Obesity
0.350 AlteredExpression disease BEFREE We identified four miRNAs overexpressed in obesity (miR-222, miR-142-3, miR-140-5p, and miR-143) and two miRNAs (miR-122 and miR-34a) overexpressed in children with obesity and nonalcoholic fatty liver disease (NAFLD) and/or insulin resistance. 31783635 2019
CUI: C0028754
Disease: Obesity
Obesity
0.350 Biomarker disease BEFREE Epigenetic origin of the link between obesity and breast cancer (BC) is investigated in a cohort of Tunisian patients, focusing on polymorphism at germline level (miR-146a) and on expression in mammary tumors (miR-21, miR-146a, and miR-34a), according to body mass index (BMI) and clinico-pathologic features. 30303554 2019
CUI: C0028754
Disease: Obesity
Obesity
0.350 Biomarker disease BEFREE Recent microRNA (miR) studies have revealed that aberrantly elevated miR-34a in obesity directly targets β-Klotho, the obligate coreceptor for both FGF19 and FGF21, and attenuates metabolic signaling of these hormones. 27125742 2016
CUI: C0028754
Disease: Obesity
Obesity
0.350 Biomarker disease CTD_human Hepatic overexpression of miR-34a reduced NAMPT/NAD(+) levels, increased acetylation of the SIRT1 target transcriptional regulators, PGC-1α, SREBP-1c, FXR, and NF-κB, and resulted in obesity-mimetic outcomes. 23834033 2013
CUI: C0028754
Disease: Obesity
Obesity
0.350 Biomarker disease BEFREE These results indicate that aberrantly elevated miR-34a in obesity attenuates hepatic FGF19 signaling by directly targeting βKL. 22988100 2012
CUI: C0271650
Disease: Impaired glucose tolerance
Impaired glucose tolerance
0.310 Biomarker phenotype BEFREE The molecular mechanism under the glucose intolerance responses which affects the growth performance and feed utilization is still confused. miR-34a was reported as a key regulator in the glucose metabolism, but how did the miR-34a exert its function in the metabolism of glucose/insulin in <i>M. amblycephala</i> was still unclear. 30115855 2018